Charles River Laboratories (Massachusetts) Announces Fourth-Quarter and Full-Year 2012 Results from Continuing Operations
Published: Feb 14, 2013
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2012. For the quarter, net sales from continuing operations were $280.1 million, a decrease of 3.7% from $291.0 million in the fourth quarter of 2011. On a segment basis, sales decreased in the Research Models and Services (RMS) segment, but were essentially unchanged in the Preclinical Services (PCS) segment.